Kamada (KMDA) Cash from Financing Activities (2013 - 2026)
Kamada (KMDA) reported Cash from Financing Activities of -$856000.0 for Q1 2026, down 192.15% on a YoY basis from $928918.5 in Q1 2025, and up 27.4% quarter-over-quarter from -$1.2 million in Q4 2025.
Kamada (KMDA) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Kamada has reported Cash from Financing Activities for 14 years, with the latest figure at -$856000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 192.15% year-over-year to -$856000.0; the trailing twelve-month figure through Mar 2026 stood at -$18.9 million (down 123.37% YoY), and the FY2025 full-year result was -$18.3 million, down 31.87% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$856000.0, up from -$1.2 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $31.3 million in Q3 2023, with the low at -$16.1 million in Q2 2025.
- Historically, Cash from Financing Activities has averaged -$961184.8 across 5 years, with a median of -$1.6 million in 2023.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 1384222.07% — and 2024, when it tumbled 199101.67%.
- Kamada's Cash from Financing Activities stood at -$2.9 million in 2022, then surged by 44.93% to -$1.6 million in 2023, then surged by 55.22% to -$708000.0 in 2024, then sank by 66.53% to -$1.2 million in 2025, then climbed by 27.4% to -$856000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$856000.0 (Q1 2026), -$1.2 million (Q4 2025), and -$754000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | Kamada | 504.70 | -73.15 Mn | 19.12 Mn | -856,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -856,000.00 |
| Mar 31, 2026 | -856,000.00 |
| Dec 31, 2025 | -1.18 Mn |
| Dec 31, 2025 | -1.18 Mn |
| Sep 30, 2025 | -754,000.00 |
| Sep 30, 2025 | -754,000.00 |
| Jun 30, 2025 | -16.12 Mn |
| Jun 30, 2025 | -16.12 Mn |
| Mar 31, 2025 | -293,000.00 |
| Mar 31, 2025 | -293,000.00 |
| Dec 31, 2024 | -708,000.00 |
| Dec 31, 2024 | -708,000.00 |
| Sep 30, 2024 | -4.79 Mn |
| Sep 30, 2024 | -4.79 Mn |
| Jun 30, 2024 | -2.68 Mn |
| Jun 30, 2024 | -2.68 Mn |
| Mar 31, 2024 | -5.74 Mn |
| Mar 31, 2024 | -5.74 Mn |
| Dec 31, 2023 | -1.58 Mn |
| Dec 31, 2023 | -1.58 Mn |